TCMD at a glance
TACTILE SYSTEMS TECHNOLOGY INC (TCMD, SEC CIK 1027838) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 10, 2026 and Form 4 insider filings as recently as August 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), TACTILE SYSTEMS TECHNOLOGY INC (TCMD) reported revenue of $329.5 million (up 12.5% from FY2024) and net income of $19.1 million. Diluted EPS was $0.82.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding TACTILE SYSTEMS TECHNOLOGY INC (TCMD) shares worth $265.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Dodd Sheri Louise on August 10, 2026 of 10,978 shares at $29.44 per share.
- In the last 90 days, TCMD insiders reported 0 open-market purchases ($0) and 1 open-market sale ($323K) on Form 4, a net sale of $323K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $329.5M
- +12.5% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$323K
- 13F holders
- 28 funds
- $265.8M · −1 vs prior quarter
- Latest 8-K
- Aug 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $85.7M, up 9% YoY from $78.9M, led by lymphedema products at $73.6M, up 12%
- Gross margin 76% vs 75% YoY; operating margin 8% vs 5%; net income $7.8M vs $3.2M
- Worst-performing line airway clearance products, $12.1M revenue, down 7% from $12.9M on DME inventory timing
- Cash $69.9M vs $81.5M YoY; operating cash flow $2.9M vs $15.2M
- Capital deployment: $6.2M LymphaTech acquisition, $3.0M MyoSleeve agreement, $6.4M share repurchases
Risk Factors
- No material changes in risk factors from the December 31, 2025 Form 10-K
- Newly added risks: none identified for the quarter ended June 30, 2026
- Regulatory, legal, and compliance risks: no quarter-specific updates disclosed
- Operational, competitive, and market risks: prior 10-K disclosures remain applicable
- Financial risks: prior 10-K disclosures remain applicable
AI summary of the TCMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal-quarter operating results announced August 10, 2026
- Press release containing financial results and condition attached as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue rose 9% to $85.7M, led by lymphedema growth of 12% to $73.6M
- Gross margin expanded to 76% from 75%, while net income increased to $7.8M from $3.2M
Item 7.01: Regulation FD Disclosure
- Item 7.01 contains only a Regulation FD non-incorporation disclaimer
- No substantive operating, financial, or shareholder-impacting disclosure in the provided text
Item 8.01: Other Events
- Exclusive VA/DoD distribution rights for MyoSleeve, expanding TCMD’s compression portfolio into earlier-stage chronic swelling treatment
- $3 million upfront payment to ElastiMed, plus minimum purchase obligations and marketing commitments
Item EX-99.1: Item EX-99.1
- Exclusive U.S. VA and DoD distribution rights for ElastiMed’s FDA-cleared MyoSleeve wearable compression device
- $3 million upfront payment plus minimum purchase obligations and marketing commitments, creating near-term cash and execution requirements
Item 5.07: Submission of Matters to a Vote of Security Holders
- All nine director nominees elected through 2027 annual meeting, with votes for ranging from 15,377,180 to 15,753,768
- Grant Thornton LLP auditor appointment ratified for 2026, with 18,499,882 votes for and 126,747 against
AI summaries of TCMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TCMD
Don't miss the next TCMD filing
- Alerts as it files. A push when TCMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TCMD, by share count.
- Ask anything. An AI agent that reads every TCMD filing and answers with sources.
TCMD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Dodd Sheri Louise | Sell | Aug 10, 2026 | 10,978 | $29.44 |
| Asbury Valerie L. | A | May 6, 2026 | 6,521 | - |
| Shafer David Brent | A | May 6, 2026 | 6,521 | - |
| King Laura G. | A | May 6, 2026 | 6,521 | - |
| Pearson Andrea | A | May 6, 2026 | 6,521 | - |
| BURKE WILLIAM W | A | May 6, 2026 | 6,521 | - |
| Washington Boyd Vindell | A | May 6, 2026 | 6,521 | - |
| Volkart Carmen B | A | May 6, 2026 | 6,521 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $293.0M | $329.5M |
| Gross Profit | - | $216.7M | $250.1M |
| Operating Income | - | $22.2M | $29.3M |
| Net Income | - | $17.0M | $19.1M |
| Gross Margin | - | 74.0% | 75.9% |
| Op. Margin | - | 7.6% | 8.9% |
| Net Margin | - | 5.8% | 5.8% |
| Balance Sheet | |||
| Total Assets | $281.4M | $297.9M | $273.9M |
| Equity | $193.6M | $216.6M | $218.9M |
| ROE | - | 7.8% | 8.7% |
| Per Share | |||
| EPS | - | $0.70 | $0.82 |
| Cash Flow | |||
| Operating CF | - | $40.7M | $42.8M |
| CapEx | - | $2.4M | $2.4M |
Source: XBRL data in TACTILE SYSTEMS TECHNOLOGY INC (TCMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TCMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $265.8M |
| Q1 2026 | 29 | $235.8M |
| Q4 2025 | 28 | $250.9M |
| Q3 2025 | 25 | $131.9M |
| Q2 2025 | 28 | $94.1M |
| Q1 2025 | 24 | $98.6M |
| Q4 2024 | 20 | $83.0M |
| Q3 2024 | 15 | $44.8M |
- BlackRock+125.6K (+7%)
- JPMorgan Chase & Co+115.6K (+231%)
- Franklin Resources+42.9K (+31%)
- Vanguard Portfolio Management LLC+38.2K (+6%)
- Raymond James Financial+31.7K (+48%)
- Morgan Stanley−403.5K (-29%)
- Goldman Sachs Group−57.3K (-19%)
- Invesco Ltd−51.1K (-42%)
- Prudential Financial−45.1K (-20%)
- Renaissance Technologies LLC−36.8K (-7%)
- U.S. Bancorp−11
Source: 13F-HR filings on SEC EDGAR (aggregated from 197 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TCMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 4 | Mar 11, 2026 | - | - | - |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 4 | Feb 26, 2026 | - | - | - |
| 4 | Feb 26, 2026 | - | - | - |
| 4 | Feb 26, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 23, 2026 | - | - | - |
| 8-K | Feb 17, 2026 | - | - | |
| 10-K | Feb 17, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
TCMD SEC filings: frequently asked questions
Are TCMD insiders buying or selling?
In the last 90 days, TACTILE SYSTEMS TECHNOLOGY INC (TCMD) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $323,243 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TCMD stock?
As of June 30, 2026, the largest TACTILE SYSTEMS TECHNOLOGY INC (TCMD) holders among the 13F filers tracked by SignalX were BlackRock ($56.7 million), Dimensional Fund Advisors ($32.5 million), Morgan Stanley ($29.2 million), Vanguard Capital Management LLC ($28.9 million), Vanguard Portfolio Management LLC ($21.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TCMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), TACTILE SYSTEMS TECHNOLOGY INC (TCMD) reported revenue of $329.5 million (up 12.5% from FY2024) and net income of $19.1 million. Diluted EPS was $0.82. The figures come from the XBRL data in the 10-K.
What did TCMD report in its latest 8-K?
TACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed an 8-K on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal-quarter operating results announced August 10, 2026.
What are the latest TCMD SEC filings?
TACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 10, 2026 and a Form 4 insider filing on August 12, 2026.
What is TCMD's SEC CIK number?
TACTILE SYSTEMS TECHNOLOGY INC (TCMD)'s SEC Central Index Key (CIK) is 1027838. EDGAR lists every TCMD filing under that number.
Ask anything about TCMD
The research agent reads TCMD's filings, financials, insider trades and 13F holders, then answers with sources.